featured
Sorafenib Increases PFS in Advanced and Refractory Desmoid Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sorafenib for Advanced and Refractory Desmoid Tumors
N. Engl. J. Med 2018 Dec 20;379(25)2417-2428, MM Gounder, MR Mahoney, BA Van Tine, V Ravi, S Attia, HA Deshpande, AA Gupta, MM Milhem, RM Conry, S Movva, MJ Pishvaian, RF Riedel, T Sabagh, WD Tap, N Horvat, E Basch, LH Schwartz, RG Maki, NP Agaram, RA Lefkowitz, Y Mazaheri, R Yamashita, JJ Wright, AC Dueck, GK SchwartzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.